MedTrace Logo

Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac

NCT00450554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2012-03-27

No results posted yet for this study

Summary

The main objective of the study is to estimate the proportion of children, born between the 01/01/2002 and the 06/23/200, living around Dieppe (cantons Dieppe est, Dieppe Ouest and Offranville), vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (\>= 4), before and after the third MenBvac vaccination.

Conditions

  • Vaccination

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • CARON François, Professor · Service des Maladies Intectieuses et Tropicales

Eligibility

Min Age
2 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00450554 on ClinicalTrials.gov